Stereotaxis to Present at 37th Annual Roth Conference

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced its participation in the 37th Annual ROTH Conference in Dana Point, California. Chairman and CEO David Fischel will be available for one-on-one meetings on March 17th, 2025.

The company's innovative technology has been utilized to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions. Stereotaxis specializes in developing robotic systems, instruments, and information solutions for the interventional laboratory, focusing on enhancing physician capabilities through robotic precision and safety, while expanding access to minimally invasive therapy and improving operating room productivity and connectivity.

ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the 37^th Annual ROTH Conference in Dana Point, California.

Mr. Fischel will be available for one-on-one meetings on Monday, March 17^th, 2025.

“We appreciate the opportunity to participate in the Roth Conference and to share Stereotaxis’ differentiated technology and growth strategy with the investment community,” says Mr. Fischel.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

When is Stereotaxis (STXS) presenting at the ROTH Conference 2025?

Stereotaxis CEO David Fischel will be available for one-on-one meetings at the 37th Annual ROTH Conference on March 17th, 2025, in Dana Point, California.

How many patients have been treated using Stereotaxis (STXS) technology?

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions.

What is the main focus of Stereotaxis (STXS) surgical robotics technology?

Stereotaxis focuses on surgical robotics for minimally invasive endovascular intervention, developing robotic systems, instruments, and information solutions for the interventional laboratory.

Where is Stereotaxis (STXS) technology currently being used?

Stereotaxis technology is being utilized globally, with presence across the United States, Europe, Asia, and other regions.

What are the key benefits of Stereotaxis (STXS) robotic systems?

The technology provides robotic precision and safety for physicians, expands access to minimally invasive therapy, and enhances productivity, connectivity, and intelligence in the operating room.